Application of Lipa inhibitor in preparation of preparation for improving atherosclerosis and application of Lipa and ApoE double-gene deletion mouse in atherosclerosis disease model
Through Lipa inhibitor and Lipa and ApoE dual gene deletion mouse model, the role of Lipa gene in atherosclerosis was studied, and the specific problems of atherosclerosis treatment in the prior art were solved, and new therapeutic targets were provided and mechanism research resources have achieved effective mitigation of atherosclerotic plaque development and reduced macrophage proportion.
Patent Information
- Application Number
- CN202411051844.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-01
- Publication Date
- 2024-12-03
AI Technical Summary
The prior art lacks specific prevention and treatment measures for plaque sites in the treatment of atherosclerosis, and the mechanism of atherosclerosis is not completely clear, making it difficult to clarify the efficacy and safety.
Develop Lipa inhibitors to prepare preparations for improved atherosclerosis, and build a mouse model of Lipa and ApoE dual gene deletion. Through gene knockout technology, study the role of Lipa gene in atherosclerosis, explore new therapeutic targets and interventions measure.
Successfully constructed a viable Lipa deletion and atherosclerosis model mice, and found that Lipa gene deletion or lack of Lipa gene can effectively reduce the development of atherosclerosis plaques and the proportion of macrophages, providing new therapeutic targets and atherosclerosis Resources for research on sample hardening mechanism.
Smart Images

Figure CN119055772A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the application of Lipa inhibitor in preparing a preparation for improving atherosclerosis and the application of Lipa and ApoE double gene-deficient mice in an atherosclerosis disease model, belonging to the technical field of genetic engineering and genetic modification. Background Art
[0002] In recent years, according to the results of the Global Burden of Disease Study, cardiovascular diseases are the diseases with the highest mortality rate worldwide, of which more than 80% of deaths are caused by ischemic heart disease and stroke. Similarly, the prevalence of cardiovascular diseases has risen rapidly in China, with the number of patients currently approaching 290 million, accounting for more than 40% of the total population deaths. Both ischemic heart disease and stroke are closely related to atherosclerosis (AS).
[0003] Atherosclerosis refers to the phenomenon that lipid deposition occurs in the intima of large and medium-sized arteries, the intima thickens, and then plaques gradually form, which reduces the elasticity of the arteries and narrows the lumen. As people study, they find that atherosclerosis is not just a single disease, but a complex physiological process. This disease usually affects large and medium-sized arteries, especially those muscular arteries with poor elasticity. This disease process occurs due to the disorder of fat metabolism and the disorder of neurovascular function. Over time, it may lead to serious consequences such as thrombosis and blood supply disorders.
[0004] In terms of age distribution, atherosclerosis is more common in men over 40 years old and postmenopausal women. The vascular endothelial "injury-response theory" is the mechanism of arterial plaque formation that is currently more recognized by the academic community: LDL-C enters the arterial wall through damaged endothelial cells and aggregates, and forms foam cells in the arterial wall through the action of inflammatory cells, which together with the fibrous cap formed by the proliferation of vascular smooth muscle cells lead to the formation of atherosclerosis, clarifying that "atherosclerosis is an inflammatory disease." According to biochemical, vascular biological, clinical and epidemiological studies in recent years, the interaction between cytokines and inflammation, endothelial dysfunction and insulin resistance plays a very important role in the pathophysiological process of atherosclerosis, which ultimately leads to metabolic disorders and the occurrence and development of atherosclerotic diseases. It can be seen that antioxidant and anti-inflammatory treatments are also important measures to prevent and treat atherosclerosis.
[0005] At present, the main means of treating atherosclerosis is to control hypertension and hyperlipidemia. In Western medicine, statins are the first choice for the treatment of atherosclerosis. Clinical treatment is mainly based on lifestyle intervention, medication, and surgical treatment. However, they cannot specifically accumulate in plaque sites, prevent plaque rupture, and eliminate plaques. In addition, the efficacy, benefits after drug withdrawal, and safety of long-term medication are still unclear. Because atherosclerotic diseases involve the complex immune system in the body, the mechanism of their occurrence and development in the body is not clear. Therefore, further clarifying the mechanism of atherosclerosis and finding effective intervention measures is an urgent problem in the current field of cardiovascular disease. Summary of the invention
[0006] The first purpose of the present invention is to provide the use of Lipa inhibitors in the preparation of preparations for improving atherosclerosis, and to provide new potential targets for the treatment of cardiovascular diseases in the prior art.
[0007] The second object of the present invention is to provide a use of a Lipa and ApoE double gene deficient mouse in an atherosclerosis disease model, thereby providing an available resource for atherosclerosis model animals in the prior art.
[0008] In order to achieve the above-mentioned purpose, the technical scheme of the application of the Lipa inhibitor of the present invention in the preparation of a preparation for improving atherosclerosis is:
[0009] Application of Lipa inhibitors in the preparation of preparations for improving atherosclerosis.
[0010] The beneficial effect of the above technical scheme is that the application of the Lipa inhibitor of the present invention in the preparation of the preparation for improving atherosclerosis is a pioneering invention. The present invention successfully obtained an atherosclerosis mouse model with Lipa gene deletion, and used it as the research object. It was found that only the homozygous mice with Lipa and ApoE double gene knockout had significantly enlarged spleen and liver, which is similar to the phenotype of cholesterol ester deposition disease caused by human lack of Lipa, while the liver and spleen of ApoE knockout homozygous and Lipa gene deletion heterozygous mice were not significantly enlarged. Moreover, whether it is the complete absence of Lipa or the lack of Lipa, it can effectively reduce the development of atherosclerotic plaques and reduce the proportion of macrophages in atherosclerotic plaques. This fully demonstrates that the Lipa gene is a key gene in the development of atherosclerosis, and inhibiting its expression can effectively improve atherosclerosis, and can be used to prepare preparations for improving atherosclerosis. The present invention provides a new potential therapeutic target for the development of atherosclerotic diseases, and lays a foundation for further clarifying the mechanism of atherosclerosis and finding effective intervention measures.
[0011] Specifically, LIPA is a key lysosomal enzyme that hydrolyzes cholesterol and triglycerides. Clinical studies have found that patients with Wolman disease who have completely lost LIPA function die of liver failure in the first year after birth, and patients with cholesterol ester storage disease who have incomplete LIPA function show hepatosplenomegaly. In the early stage, through whole genome scanning and association analysis of atherosclerosis patients and normal human blood vessels, it was found that Lipa gene mutations were extremely significantly correlated with atherosclerosis. However, previous studies have found that the mortality rate of Lipa knockout mice is extremely high, and almost all Lipa-deficient mice die before adulthood, and there is no report on Lipa-deficient atherosclerosis inflammation mouse model. The present invention successfully constructs survivable Lipa-deficient and deficient atherosclerosis model mice, and homozygous mice with Lipa gene deficiency have significantly enlarged spleen and liver, which is similar to the phenotype of cholesterol ester deposition disease caused by human deficiency of Lipa. Therefore, it is used to study the potential mechanism of Lipa deficiency or deficiency for cholesterol ester storage disease and atherosclerosis, which can provide new models and potential targets for the treatment of cholesterol ester storage disease and cardiovascular disease.
[0012] As a further improvement, the preparation for improving atherosclerosis is a preparation for slowing down the formation of atherosclerotic plaques.
[0013] As a further improvement, the preparation for improving atherosclerosis is a preparation for reducing the proportion of macrophages in atherosclerotic plaques.
[0014] Specifically, Lipa inhibitors are preparations in the prior art that can effectively inhibit Lipa activity and preparations that inhibit Lipa gene expression (such as siRNA, gRNA, etc. that can inhibit Lipa gene expression).
[0015] In order to achieve the above-mentioned purpose, the technical scheme of using the Lipa and ApoE double gene-deficient mice as atherosclerosis model mice of the present invention is:
[0016] Application of a Lipa and ApoE double-gene deficient mouse in an atherosclerotic disease model.
[0017] The beneficial effect of the above technical solution is that: the present invention successfully constructs Lipa and ApoE double gene deletion mice for the first time, and through detection, it is found that atherosclerotic plaques can be formed after high-fat feeding, and whether it is complete loss of Lipa or lack of Lipa, it can effectively reduce the development of atherosclerotic plaques and reduce the proportion of macrophages in atherosclerotic plaques. The Lipa and ApoE double gene deletion mice of the present invention provide a new animal model for studying the occurrence and development of atherosclerotic diseases, screening of drugs for treating atherosclerosis, etc.
[0018] As a further improvement, the method for constructing the Lipa and ApoE double gene-deficient mice is as follows: using CRISPR / Cas9 genome editing technology, the Lipa gene in mice is knocked out in the ApoE gene-knockout mouse background to obtain F0 generation mice; the F0 generation mice are backcrossed with the ApoE gene-knockout mice and then self-crossed to obtain homozygous Lipa and ApoE double gene-deficient mice.
[0019] As a further improvement, the Lipa gene knockout site is as follows:
[0020] Lipa-sgRNA1: 5'-AAGCTCAAACATGCCGCTCA GGG-3' (as shown in SEQ ID NO. 1);
[0021] Lipa-sgRNA2: 5'-TTTTTAAAAGAGACATGTCG AGG-3' (as shown in SEQ ID NO. 2);
[0022] Lipa-sgRNA3: 5'-CAGGGGGGCTCGGTAAGTTA AGG-3' (as shown in SEQ ID NO. 3);
[0023] Lipa-sgRNA4: 5′-TAGGCGGGCTTTAAGATTCC CGG-3′ (as shown in SEQ ID NO. 4). BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 Schematic diagram of Lipa gene knockout and DNA sequencing analysis results in Example 1 of the present invention (wherein (A) is a schematic diagram of Lipa gene knockout, (B) is a DNA sequencing analysis showing the expected Lipa knockout, and the red dotted line corresponds to the missing base sequence);
[0025] Figure 2 The blood lipid and organ index detection of atherosclerotic mice with double deletion of ApoE and Lipa in Example 2 of the present invention (wherein (A) is wild type (ApoE - / - ), heterozygous (Lipa + / - ApoE - / - ) and homozygous (Lipa - / - ApoE - / - ) Body weights of the three groups of mice fed with high-fat diet for 12 weeks. (B) shows the serum biochemical indexes of the three groups of mice. (C) and (E) show the representative images of the liver and spleen of the three groups of mice. (D) and (F) show the weights and organ indexes of the liver and spleen of the three groups of mice. * represents P<0.05, ** represents P<0.01, *** represents P<0.001, **** represents P<0.0001, and ns represents no significant difference).
[0026] Figure 3 Pathological detection of aorta in atherosclerotic mice lacking Lipa in Example 3 of the present invention ((A) and (B) are wild-type (ApoE - / - ), heterozygous (Lipa + / - ApoE - / - ) and homozygous (Lipa - / - ApoE - / - ) The representative image of the descending aorta and the statistical image of plaques in the three groups of mice after high-fat feeding for 12 weeks. (C) and (D) are the representative images of the aorta root stained with Oil Red O and the statistical image of plaques in the three groups of mice, respectively. ** represents P<0.01, *** represents P<0.001, and ns represents no significant difference);
[0027] Figure 4 Detection of aortic root macrophages in atherosclerotic mice with double deletion of ApoE and Lipa in Example 4 of the present invention ((A) and (B) are representative images and statistical graphs of CD68 immunohistochemistry of aortic root of three groups of mice, (C) and (D) are representative images and statistical graphs of flow cytometry analysis of aortic macrophages of three groups of mice, * represents P < 0.05, ** represents P < 0.01, *** represents P < 0.001, ns represents no significant difference). DETAILED DESCRIPTION
[0028] Atherosclerosis is closely related to the occurrence and development of cardiovascular and cerebrovascular diseases, which are the diseases with the highest mortality rate in the world. Therefore, studying the occurrence and development of atherosclerosis is crucial to the treatment of cardiovascular and cerebrovascular diseases. However, atherosclerotic diseases involve a complex immune system in the body, and the mechanism of their occurrence and development in the body is not completely clear. Based on this, the present invention provides the use of Lipa inhibitors in the preparation of preparations for improving atherosclerosis.
[0029] The present invention has found through a large number of previous studies and investigations that Lipa is highly expressed in monocytes and macrophages of individuals with risk alleles, and atherosclerosis is a chronic inflammatory disease, and immune cells may have an impact on the progression of atherosclerotic diseases. Therefore, the present invention first constructs an atherosclerosis mouse model with double knockout of ApoE and Lipa genes, and uses it as a research object to clarify the role of the Lipa gene in the development of atherosclerosis. It was found through detection that only the spleen and liver of homozygous mice with double deletion of ApoE and Lipa genes were significantly enlarged, which is similar to the phenotype of cholesterol ester deposition caused by human lack of Lipa, while the liver and spleen of heterozygous mice with homozygous deletion of ApoE gene and deletion of Lipa gene were not significantly enlarged. Moreover, whether it is the complete absence of Lipa or the lack of Lipa, it can effectively reduce the development of atherosclerotic plaques and reduce the proportion of macrophages in atherosclerotic plaques. This fully shows that the Lipa gene is a key gene in the development of atherosclerosis, and inhibiting its expression can effectively improve atherosclerosis, which can be used as a therapeutic target for improving atherosclerosis. The present invention provides a new potential therapeutic target for the development of atherosclerosis, and lays a foundation for further clarifying the occurrence mechanism of atherosclerosis and finding effective intervention measures.
[0030] The present invention is further described below in conjunction with specific embodiments, but the protection scope of the present invention is not limited thereto; however, these embodiments are only examples and do not constitute any limitation on the scope of the present invention. The details and forms of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the protection scope of the present invention. The experimental methods in the following embodiments, unless otherwise specified, are conventional methods, such as referring to the Molecular Cloning Laboratory Manual (Sambrook J & Russell DW. Molecular cloning: a laboratory manual. 2001) compiled by Sambrook et al., or the instructions provided by the product manufacturer. The experimental materials used in the following embodiments, unless otherwise specified, are purchased from conventional biochemical reagent manufacturers.
[0031] ApoE used in the following examples - / - ApoE knockout mice were purchased from Beijing Weitonglihua Experimental Animal Co., Ltd.
[0032] Specific examples of the use of the Lipa inhibitor of the present invention in the preparation of a preparation for improving atherosclerosis and the use of Lipa and ApoE double gene-deficient mice in an atherosclerosis disease model:
[0033] In order to study the role of Lipa gene in the development of atherosclerosis, the present invention firstly constructed a double knockout mouse model of Lipa gene and ApoE gene, and used it as the research object to study the process of atherosclerosis. The specific implementation operation is as follows:
[0034] Example 1 Lipa and ApoE gene deletion (Lipa - / - ApoE - / - ) Construction of mice
[0035] In this example, targeting sgRNA was designed for the mouse Lipa gene (eg Figure 1 As shown in the figure, sgRNA and Cas9 mRNA are injected into the fertilized oocytes of ApoE knockout mice through a microinjection system, and the surviving fertilized oocytes are transplanted into the oviducts of pseudo-pregnant female mice to construct mice, which specifically includes the following steps:
[0036] 1. Determination of the targeting sequence
[0037] According to the principle of CRISPR / Cas9 system, CRISPOR online design software was used to determine the specific target sites Lipa-sgRNA1, Lipa-sgRNA2, Lipa-sgRNA3, and Lipa-sgRNA4 of the mouse gene to be knocked out Lipa (Gene ID: 96789).
[0038] Specifically, the mouse Lipa (TranscriptID: ENSMUST00000049572.15) gene DNA sequence was found in the mouse genome database ensembl (http: / / asia.ensembl.org), and then the online design software CRISPOR (http: / / crispor.tefor.net / crispor.cgi) was used to select 2 (4 in total) specific sites before exon4 and after exon7 of the mouse Lipa gene as the target sequences of sgRNA. The target sequences are:
[0039] Lipa-sgRNA1: 5'-AAGCTCAAACATGCCGCTCAGGG-3' (as shown in SEQ ID NO. 1);
[0040] Lipa-sgRNA2: 5'-TTTTTAAAAGAGACATGTCGAGG-3' (as shown in SEQ ID NO. 2);
[0041] Lipa-sgRNA3: 5'-CAGGGGGGCTCGGTAAGTTAAGG-3' (as shown in SEQ ID NO. 3);
[0042] Lipa-sgRNA4: 5′-TAGGCGGGCTTTAAGATTCCCGG-3′ (as shown in SEQ ID NO. 4).
[0043] 2. Biosynthesis of sgRNA and Cas9 mRNA
[0044] Biosynthesis was provided by Nanjing GenScript Biotech Co., Ltd.
[0045] 3. Microinjection
[0046] The obtained sgRNA and Cas9 mRNA were injected into mouse fertilized oocytes through a microinjection system.
[0047] Specifically, by measuring the ApoE - / - Female mice were injected with hormones, and fertilized oocytes were obtained after superovulation and mating. The four sgRNAs and Cas9 mRNA were diluted to a final concentration of 50 ng / μL using RNase-free ultrapure water (Invitrogen, 10977015), mixed and injected into the ApoE - / - The fertilized egg cells of background mice are placed in an incubator (37°C, CO2 concentration of 5%) for 1 hour, and then the surviving cells are selected and transplanted into the oviducts of pseudo-pregnant ICR mice. Founder mice can be obtained 20 days later.
[0048] 4. Founder mouse genotype identification and sequencing verification
[0049] The tails of the obtained founder mice were cut, DNA was extracted, and then the DNA was used as template DNA for PCR amplification using primers. The primer sequences used were:
[0050] Lipa-F1: 5'-TGTTCCTGTACATGCTTAGCCTT-3' (as shown in SEQ ID NO. 5);
[0051] Lipa-R1: 5'-CTGTTCTACCAGTCGCATTGTG-3' (as shown in SEQ ID NO. 6);
[0052] Lipa-F2: 5'-AGGCCTTTCACTTGCTTGGT-3' (as shown in SEQ ID NO. 7);
[0053] Lipa-R2: 5'-CTGACTCAGCTCCCCAAGTG-3' (as shown in SEQ ID NO. 8);.
[0054] The PCR reaction system was as follows: the template was mouse tail DNA, 20 ng was added; 2 μL of upstream primer was added; 2 μL of downstream primer was added; 25 μL of 2×Taq Master Mix (purchased from vazyme, P111-01) was added; and H2O was supplemented to a total volume of 50 μL.
[0055] The PCR reaction program is: 94°C, 5min; 94°C, 30s, 60°C, 30s, 72°C, 30s, 30 cycles; 72°C, 10min. Among them, when the Lipa-F1+Lipa-R1 primer combination is used for amplification, only the wild type and heterozygous genotypes will have a 392bp amplification band (as shown in SEQ ID NO.9); when the Lipa-F2+Lipa-R2 primer combination is used for amplification, only the knockout homozygous and heterozygous genotypes will have a 231bp amplification band (as shown in SEQ ID NO.10). According to the amplification results of the two pairs of primers, it is possible to determine whether the mouse genotype is Lipa wild type, knockout heterozygous or knockout homozygous.
[0056] After obtaining the PCR product, take 2 μL of the product for electrophoresis detection. If there is a band, the PCR product will be sent for sequencing.
[0057] Depend on Figure 1 It can be seen that in the obtained Founder mice, there is a deletion of 11,560 bases in the Lipa gene.
[0058] 5. After backcrossing the F0 generation mice (i.e., founder mice) with the ApoE knockout mice, the offspring were selected to select the Lipa knockout heterozygous and ApoE knockout homozygous mice (Lipa + / - ApoE - / - ), and then self-fertilized to obtain homozygous mice with double deletion of Lipa and ApoE (Lipa - / - ApoE - / - ).
[0059] Example 2 Construction of an atherosclerosis mouse model with double deletion of Lipa and ApoE genes and detection of biochemical indicators
[0060] This example uses the Lipa constructed in Example 1 - / - ApoE - / - (homozygous for deletion of Lipa and ApoE genes) and Lipa + / - ApoE - / - The mice (heterozygous for Lipa gene deletion and homozygous for ApoE gene deletion) were used as the research subjects. A mouse model of atherosclerosis with double gene deletion of Lipa and ApoE was established by high-fat feeding, and its biochemical indicators were detected, which specifically included the following steps:
[0061] Lipa constructed in Example 1 - / - ApoE - / - and Lipa + / - ApoE - / - The mice were fed a high-fat diet for 12 weeks starting from 7-8 weeks of age. The high-fat diet contained 21% fat, 1.25% cholesterol, 21% protein, and 50% carbohydrates. The weight of the mice was measured during this period.
[0062] Note: ApoE - / - (ApoE gene-deficient homozygous) mice served as the control group in subsequent experiments.
[0063] After 12 weeks of high-fat feeding, the mice were anesthetized, weighed and blood was collected from their eyeballs. The chest and abdominal cavities were then opened with blunt-tipped scissors to expose the internal organs, and the iliac artery on one side was cut. A precision peristaltic pump was used to perform cardiac perfusion with heparinized saline to flush the blood in the mouse blood vessels until the outflowing liquid was colorless and transparent, and then the liver and kidneys were removed and weighed and recorded.
[0064] After the non-anticoagulated blood of mice was centrifuged and allowed to stand for 40 min, the serum was transferred to a new 1.5 mL centrifuge tube at room temperature, 2000 rpm, for 10 min. The concentrations of TG (triglycerides), TC (total cholesterol), LDL (low-density lipoprotein) and HDL (high-density lipoprotein) in the serum were analyzed using an automatic biochemical analyzer.
[0065] The results are as follows Figure 2 As shown in the figure, after 12 weeks of high-fat feeding, Lipa - / - ApoE - / - The mice had a significant weight reduction, and their liver and spleen were significantly enlarged, which were similar to the clinical symptoms of Lipa-deficient patients. However, the total cholesterol level in their serum was significantly reduced. The liver / spleen of heterozygous mice did not show significant enlargement, and there were no significant changes in the four blood lipid items.
[0066] Example 3 Detection of atherosclerotic plaques
[0067] This example uses the mouse model constructed in Example 2 as a research object to detect atherosclerotic plaques, specifically including the following steps:
[0068] (1) Place the mouse under a dissecting microscope, remove the mouse heart first, and immerse it in OCT embedding medium for subsequent frozen sectioning and oil red staining. Remove the mouse aorta completely, remove the surrounding excess fat, lymph nodes and other tissues, cut the aorta longitudinally with ophthalmic scissors and fix it in a glass plastic dish for subsequent oil red O staining.
[0069] (2) Add 4% PFA (paraformaldehyde) to completely cover the aorta on the glass dish, fix for 30 minutes, pour it out, and use absorbent paper to absorb the excess liquid on the glass dish. Weigh 0.15g of oil red powder with an electronic balance, add 30mL of isopropanol, mix upside down to completely dissolve the oil red powder, then add 20mL of MilliQ water, and filter with qualitative filter paper to obtain 0.5% Oil Red O staining working solution.
[0070] (3) Pour the Oil Red O dye solution onto the fixed glass dish so that it completely covers the aorta on the glass dish. Stain for 1 hour. Rinse the Oil Red O dye solution on the surface of the glass dish with MilliQ water and 75% alcohol, and place it under a microscope to take pictures. The specific results are as follows Figure 3 shown.
[0071] The results of the gross Oil Red O staining of the aorta and the Oil Red O staining of the aortic root showed that Lipa - / - ApoE - / - and Lipa + / - ApoE - / - The plaque area of the descending aorta and aortic root of mice was significantly reduced, indicating that both Lipa deficiency and absence can effectively slow down the development of atherosclerosis in ApoE- / - mice.
[0072] Example 4 Detection of macrophages in atherosclerotic plaques
[0073] This example uses the mouse model constructed in Example 2 as a research object to detect macrophages in atherosclerotic plaques, specifically including the following steps:
[0074] (1) Place the mouse under a dissecting microscope, remove the mouse heart, and immerse it in 4% paraformaldehyde for subsequent paraffin sectioning and immunohistochemical staining. Then remove the mouse aorta intact, place it in a culture dish, place it on ice, cut it into a milky state with ophthalmic scissors, and then transfer it to a 2 mL tube.
[0075] (2) Add 10 μL of composite collagenase and 10 μL of DNase I to each tube, place it on the previously opened Block, set the temperature to 37°C, and shake at 300 rpm for 30 min for digestion.
[0076] (3) After digestion, add Facs Buffer to each tube to terminate digestion, centrifuge at 4°C, 1500 rpm for 5 min, and discard the supernatant. Add 100 μL 2.4G2, incubate at 4°C for 20 min.
[0077] (4) After washing with FACS buffer, centrifuge at 1500 rpm for 5 min at 4°C and discard the supernatant.
[0078] (5) Add 100 μL of antibody mixture (anti-CD45 APC-eFluor780, anti-CD3PerCP-Cy5.5, anti-CD19 PerCP-Cy5.5, anti-Ly6G Alexa700, anti-CD11B SB600, anti-F4 / 80PE-Cy7, anti-CD64 APC) to each sample, incubate at 4°C in dark for 30 min, and wash twice with FACS buffer.
[0079] (6) Add 400 μL Sytox Blue, mix thoroughly by pipetting, filter, load onto flow cytometer, and analyze the results using FlowJo.
[0080] The results are as follows Figure 4 As shown, the immunohistochemistry results of CD68, a macrophage marker in the aortic root, showed that whether Lipa was missing or deficient, the proportion of macrophages in the plaque could be significantly reduced; the results of aortic flow cytometry experiments showed that whether Lipa was missing or deficient, the proportion of CD64+F4 / 80+ macrophages in the plaque could be significantly reduced. Macrophages in plaques are an important factor in promoting the development of atherosclerotic plaques, which also indicates that Lipa loss or deficiency slows down the development of atherosclerosis by reducing the proportion of macrophages in plaques.
[0081] Finally, it is noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. Application of Lipa inhibitors in the preparation of preparations for improving atherosclerosis.
2. The use of the Lipa inhibitor according to claim 1 in the preparation of a preparation for improving atherosclerosis, characterized in that: The preparation for improving atherosclerosis is a preparation for slowing down the formation of atherosclerotic plaques.
3. The use of the Lipa inhibitor according to claim 1 in the preparation of a preparation for improving atherosclerosis, characterized in that: The preparation for improving atherosclerosis is a preparation for reducing the proportion of macrophages in atherosclerotic plaques.
4. Application of a Lipa and ApoE double gene deficient mouse in an atherosclerotic disease model.
5. The use of the Lipa and ApoE double gene deficient mouse in an atherosclerotic disease model according to claim 4, characterized in that: The method for constructing the Lipa and ApoE double gene deficiency mice is as follows: using CRISPR / Cas9 genome editing technology, the Lipa gene in mice is knocked out in the ApoE gene knockout mouse background to obtain F0 generation mice; the F0 generation mice are backcrossed with the ApoE gene knockout mice and then self-crossed to obtain homozygous Lipa and ApoE double gene deficiency mice.
6. The use of the Lipa and ApoE double gene deficient mouse in an atherosclerotic disease model according to claim 5, characterized in that: The Lipa gene knockout sites are as follows: Lipa-sgRNA1: 5'-AAGCTCAAACATGCCGCTCA GGG-3' (as shown in SEQ ID NO. 1); Lipa-sgRNA2: 5'-TTTTTAAAAGAGACATGTCG AGG-3' (as shown in SEQ ID NO. 2); Lipa-sgRNA3: 5'-CAGGGGGGCTCGGTAAGTTA AGG-3' (as shown in SEQ ID NO. 3); Lipa-sgRNA4: 5′-TAGGCGGGCTTTAAGATTCC CGG-3′ (as shown in SEQ ID NO. 4).
